BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tang JT, Andrews LM, van Gelder T, Shi YY, van Schaik RH, Wang LL, Hesselink DA. Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations. Expert Opin Drug Metab Toxicol. 2016;12:555-565. [PMID: 27010623 DOI: 10.1517/17425255.2016.1170808] [Cited by in Crossref: 70] [Cited by in F6Publishing: 62] [Article Influence: 11.7] [Reference Citation Analysis]
Number Citing Articles
1 Tönshoff B. Immunosuppressive therapy post-transplantation in children: what the clinician needs to know. Expert Review of Clinical Immunology 2020;16:139-54. [DOI: 10.1080/1744666x.2020.1714437] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Andrews LM, Hesselink DA, van Schaik RHN, van Gelder T, de Fijter JW, Lloberas N, Elens L, Moes DJAR, de Winter BCM. A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients. Br J Clin Pharmacol 2019;85:601-15. [PMID: 30552703 DOI: 10.1111/bcp.13838] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
3 Andrews LM, Hesselink DA, van Gelder T, Koch BCP, Cornelissen EAM, Brüggemann RJM, van Schaik RHN, de Wildt SN, Cransberg K, de Winter BCM. A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation. Clin Pharmacokinet 2018;57:475-89. [PMID: 28681225 DOI: 10.1007/s40262-017-0567-8] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 11.7] [Reference Citation Analysis]
4 Zubiaur P, Koller D, Saiz-Rodríguez M, Navares-Gómez M, Abad-Santos F. Important Pharmacogenetic Information for Drugs Prescribed During the SARS-CoV-2 Infection (COVID-19). Clin Transl Sci 2020;13:1023-33. [PMID: 32936528 DOI: 10.1111/cts.12866] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
5 Kurzawski M, Malinowski D, Dziewanowski K, Droździk M. Analysis of common polymorphisms within NR1I2 and NR1I3 genes and tacrolimus dose-adjusted concentration in stable kidney transplant recipients. Pharmacogenetics and Genomics 2017;27:372-7. [DOI: 10.1097/fpc.0000000000000301] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
6 Miano TA, Flesch JD, Feng R, Forker CM, Brown M, Oyster M, Kalman L, Rushefski M, Cantu E 3rd, Porteus M, Yang W, Localio AR, Diamond JM, Christie JD, Shashaty MGS. Early Tacrolimus Concentrations After Lung Transplant Are Predicted by Combined Clinical and Genetic Factors and Associated With Acute Kidney Injury. Clin Pharmacol Ther 2020;107:462-70. [PMID: 31513279 DOI: 10.1002/cpt.1629] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
7 Rong Y, Mayo P, Ensom MHH, Kiang TKL. Population Pharmacokinetic Analysis of Immediate-Release Oral Tacrolimus Co-administered with Mycophenolate Mofetil in Corticosteroid-Free Adult Kidney Transplant Recipients. Eur J Drug Metab Pharmacokinet 2019;44:409-22. [PMID: 30377942 DOI: 10.1007/s13318-018-0525-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
8 Woillard JB, Mourad M, Neely M, Capron A, van Schaik RH, van Gelder T, Lloberas N, Hesselink DA, Marquet P, Haufroid V, Elens L. Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation. Front Pharmacol 2017;8:358. [PMID: 28642710 DOI: 10.3389/fphar.2017.00358] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
9 Shayan M, Elyasi S. Cilastatin as a protective agent against drug-induced nephrotoxicity: a literature review. Expert Opin Drug Saf 2020;19:999-1010. [PMID: 32666842 DOI: 10.1080/14740338.2020.1796967] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
10 Lin G, Zhang X, Zhang K, Han Y, Tan L, Li J. Evaluation of tacrolimus-related CYP3A5 genotyping in China: Results from the First External Quality Assessment Exercise. J Clin Lab Anal 2018;32:e22563. [PMID: 29708622 DOI: 10.1002/jcla.22563] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
11 Bunthof KLW, Al-Hassany L, Nakshbandi G, Hesselink DA, van Schaik RHN, Ten Dam MAGJ, Baas MC, Hilbrands LB, van Gelder T. A randomized crossover study comparing different tacrolimus formulations to reduce intrapatient variability in tacrolimus exposure in kidney transplant recipients. Clin Transl Sci 2021. [PMID: 34905302 DOI: 10.1111/cts.13206] [Reference Citation Analysis]
12 Bhasin B, Ber Ce P, Szabo A, Chhabra S, D'Souza A. Correlates and Outcomes of Early Acute Kidney Injury after Hematopoietic Cell Transplantation. Am J Med Sci 2021;362:72-7. [PMID: 33812909 DOI: 10.1016/j.amjms.2021.03.013] [Reference Citation Analysis]
13 Soeorg H, Sverrisdóttir E, Andersen M, Lund TM, Sessa M. The PHARMACOM-EPI Framework for Integrating Pharmacometric Modelling Into Pharmacoepidemiological Research Using Real-World Data: Application to Assess Death Associated With Valproate. Clin Pharmacol Ther 2021. [PMID: 34860420 DOI: 10.1002/cpt.2502] [Reference Citation Analysis]
14 Lenain R, Maanaoui M, Hamroun A, Larrue R, Van Der Hauwaert C, Gibier JB, Gnemmi V, Gomis S, Labalette M, Broly F, Hennart B, Pottier N, Hazzan M, Cauffiez C, Glowacki F. Impact of Tacrolimus Daily Dose Limitation in Renal Transplant Recipients Expressing CYP3A5: A Retrospective Study. J Pers Med 2021;11:1002. [PMID: 34683143 DOI: 10.3390/jpm11101002] [Reference Citation Analysis]
15 Andrews LM, de Winter BCM, Cornelissen EAM, de Jong H, Hesselink DA, Schreuder MF, Brüggemann RJM, van Gelder T, Cransberg K. A Population Pharmacokinetic Model Does Not Predict the Optimal Starting Dose of Tacrolimus in Pediatric Renal Transplant Recipients in a Prospective Study: Lessons Learned and Model Improvement. Clin Pharmacokinet 2020;59:591-603. [PMID: 31654367 DOI: 10.1007/s40262-019-00831-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Cai X, Song H, Jiao Z, Yang H, Zhu M, Wang C, Wei D, Shi L, Wu B, Chen J. Population pharmacokinetics and dosing regimen optimization of tacrolimus in Chinese lung transplant recipients. Eur J Pharm Sci 2020;152:105448. [PMID: 32621968 DOI: 10.1016/j.ejps.2020.105448] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
17 Ozdemir F, Oz MD, Suzen HS. A Novel PCR-RFLP Method for Detection of POR*28 Polymorphism and its Genotype/Allele Frequencies in a Turkish Population. Curr Drug Metab 2019;20:845-51. [PMID: 31518218 DOI: 10.2174/1389200220666190913121052] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Gelder TV, Etsouli O, Moes DJ, Swen JJ. Comparison of the Impact of Pharmacogenetic Variability on the PK of Slow Release and Immediate Release Tacrolimus Formulations. Genes (Basel) 2020;11:E1205. [PMID: 33076474 DOI: 10.3390/genes11101205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
19 Chen L, Prasad GVR. CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment. Pharmgenomics Pers Med 2018;11:23-33. [PMID: 29563827 DOI: 10.2147/PGPM.S107710] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
20 Yamada T, Zhang M, Masuda S. Significance of Ethnic Factors in Immunosuppressive Therapy Management After Organ Transplantation. Ther Drug Monit 2020;42:369-80. [PMID: 32091469 DOI: 10.1097/FTD.0000000000000748] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
21 Mendrinou E, Mashaly ME, Al Okily AM, Mohamed ME, Refaie AF, Elsawy EM, Saleh HH, Sheashaa H, Patrinos GP. CYP3A5 Gene-Guided Tacrolimus Treatment of Living-Donor Egyptian Kidney Transplanted Patients. Front Pharmacol 2020;11:1218. [PMID: 32848803 DOI: 10.3389/fphar.2020.01218] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Emoto C, Johnson TN, Hahn D, Christians U, Alloway RR, Vinks AA, Fukuda T. A Theoretical Physiologically-Based Pharmacokinetic Approach to Ascertain Covariates Explaining the Large Interpatient Variability in Tacrolimus Disposition. CPT Pharmacometrics Syst Pharmacol 2019;8:273-84. [PMID: 30843669 DOI: 10.1002/psp4.12392] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
23 Ling J, Dong L, Yang X, Qian Q, Jiang Y, Zou S, Hu N. Effects of CYP3A5, ABCB1 and POR*28 polymorphisms on pharmacokinetics of tacrolimus in the early period after renal transplantation. Xenobiotica 2020;50:1501-9. [DOI: 10.1080/00498254.2020.1774682] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Andrews LM, de Winter BC, Tang JT, Shuker N, Bouamar R, van Schaik RH, Koch BC, van Gelder T, Hesselink DA. Overweight Kidney Transplant Recipients Are at Risk of Being Overdosed Following Standard Bodyweight-Based Tacrolimus Starting Dose. Transplant Direct 2017;3:e129. [PMID: 28361113 DOI: 10.1097/TXD.0000000000000644] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
25 Moroni G, Ponticelli C. Synthetic pharmacotherapy for lupus nephritis. Expert Opinion on Pharmacotherapy 2016;18:175-86. [DOI: 10.1080/14656566.2016.1276563] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
26 Dapía I, García I, Martinez JC, Arias P, Guerra P, Díaz L, García A, Ochoa D, Tenorio J, Ramírez E, Román M, Gordo G, Saiz-Rodríguez M, Frías J, Abad-Santos F, Lapunzina P, Carcas AJ, Borobia AM. Prediction models for voriconazole pharmacokinetics based on pharmacogenetics: AN exploratory study in a Spanish population. Int J Antimicrob Agents 2019;54:463-70. [PMID: 31279853 DOI: 10.1016/j.ijantimicag.2019.06.026] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
27 Brunet M, van Gelder T, Åsberg A, Haufroid V, Hesselink DA, Langman L, Lemaitre F, Marquet P, Seger C, Shipkova M, Vinks A, Wallemacq P, Wieland E, Woillard JB, Barten MJ, Budde K, Colom H, Dieterlen M, Elens L, Johnson-davis KL, Kunicki PK, Macphee I, Masuda S, Mathew BS, Millán O, Mizuno T, Moes DAR, Monchaud C, Noceti O, Pawinski T, Picard N, van Schaik R, Sommerer C, Vethe NT, de Winter B, Christians U, Bergan S. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Therapeutic Drug Monitoring 2019;41:261-307. [DOI: 10.1097/ftd.0000000000000640] [Cited by in Crossref: 131] [Cited by in F6Publishing: 46] [Article Influence: 43.7] [Reference Citation Analysis]
28 Job KM, Roberts JK, Enioutina EY, IIIamola SM, Kumar SS, Rashid J, Ward RM, Fukuda T, Sherbotie J, Sherwin CM. Treatment optimization of maintenance immunosuppressive agents in pediatric renal transplant recipients. Expert Opin Drug Metab Toxicol 2021;17:747-65. [PMID: 34121566 DOI: 10.1080/17425255.2021.1943356] [Reference Citation Analysis]
29 Zhu W, Xue L, Peng H, Duan Z, Zheng X, Cao D, Wen J, Wei X. Tacrolimus population pharmacokinetic models according to CYP3A5 / CYP3A4 / POR genotypes in Chinese Han renal transplant patients. Pharmacogenomics 2018;19:1013-25. [DOI: 10.2217/pgs-2017-0139] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
30 Lloberas N, Hesselink DA, van Schaik RH, Grinyò JM, Colom H, Gelder TV, Elens L. Detection of a rare CYP3A4 variant in a transplant patient characterized by a tacrolimus poor metabolizer phenotype. Pharmacogenomics 2018;19:305-10. [PMID: 29469606 DOI: 10.2217/pgs-2017-0301] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
31 Yu M, Liu M, Zhang W, Ming Y. Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of Tacrolimus in Kidney Transplantation. Curr Drug Metab 2018;19:513-22. [PMID: 29380698 DOI: 10.2174/1389200219666180129151948] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 7.5] [Reference Citation Analysis]
32 Grinyó JM. Renal allograft performance in immigrant transplant recipients. Transpl Int 2020;33:1387-9. [PMID: 32668492 DOI: 10.1111/tri.13702] [Reference Citation Analysis]
33 Liu H, Xu Q, Huang W, Zhao Q, Jiang Z, Kuang X, Li Z, Sun H, Qiu X. CYP3A5 and CYP3A7 genetic polymorphisms affect tacrolimus concentration in pediatric patients with nephrotic range proteinuria. Eur J Clin Pharmacol 2019;75:1533-40. [DOI: 10.1007/s00228-019-02726-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
34 Del Bello A, Congy-Jolivet N, Danjoux M, Muscari F, Lavayssière L, Esposito L, Hebral AL, Bellière J, Kamar N. High tacrolimus intra-patient variability is associated with graft rejection, and de novo donor-specific antibodies occurrence after liver transplantation. World J Gastroenterol 2018; 24(16): 1795-1802 [PMID: 29713132 DOI: 10.3748/wjg.v24.i16.1795] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 27] [Article Influence: 9.3] [Reference Citation Analysis]
35 Al-Kofahi M, Oetting WS, Schladt DP, Remmel RP, Guan W, Wu B, Dorr CR, Mannon RB, Matas AJ, Israni AK, Jacobson PA. Precision Dosing for Tacrolimus Using Genotypes and Clinical Factors in Kidney Transplant Recipients of European Ancestry. J Clin Pharmacol 2021;61:1035-44. [PMID: 33512723 DOI: 10.1002/jcph.1823] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Campagne O, Mager DE, Brazeau D, Venuto RC, Tornatore KM. Tacrolimus Population Pharmacokinetics and Multiple CYP3A5 Genotypes in Black and White Renal Transplant Recipients. J Clin Pharmacol 2018;58:1184-95. [PMID: 29775201 DOI: 10.1002/jcph.1118] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
37 He Q, Bu F, Zhang H, Wang Q, Tang Z, Yuan J, Lin HS, Xiang X. Investigation of the Impact of CYP3A5 Polymorphism on Drug-Drug Interaction between Tacrolimus and Schisantherin A/Schisandrin A Based on Physiologically-Based Pharmacokinetic Modeling. Pharmaceuticals (Basel) 2021;14:198. [PMID: 33673653 DOI: 10.3390/ph14030198] [Reference Citation Analysis]
38 Shi D, Xie T, Deng J, Niu P, Wu W. CYP3A4 and GCK genetic polymorphisms are the risk factors of tacrolimus-induced new-onset diabetes after transplantation in renal transplant recipients. Eur J Clin Pharmacol 2018;74:723-9. [DOI: 10.1007/s00228-018-2442-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
39 Egeland EJ, Robertsen I, Hermann M, Midtvedt K, Størset E, Gustavsen MT, Reisæter AV, Klaasen R, Bergan S, Holdaas H, Hartmann A, Åsberg A. High Tacrolimus Clearance Is a Risk Factor for Acute Rejection in the Early Phase After Renal Transplantation. Transplantation 2017;101:e273-9. [DOI: 10.1097/tp.0000000000001796] [Cited by in Crossref: 28] [Cited by in F6Publishing: 12] [Article Influence: 5.6] [Reference Citation Analysis]
40 Mohamed ME, Schladt DP, Guan W, Wu B, van Setten J, Keating BJ, Iklé D, Remmel RP, Dorr CR, Mannon RB, Matas AJ, Israni AK, Oetting WS, Jacobson PA; DeKAF Genomics and GEN03 Investigators. Tacrolimus troughs and genetic determinants of metabolism in kidney transplant recipients: A comparison of four ancestry groups. Am J Transplant 2019;19:2795-804. [PMID: 30953600 DOI: 10.1111/ajt.15385] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
41 Dorr CR, Oetting WS, Jacobson PA, Israni AK. Genetics of acute rejection after kidney transplantation. Transpl Int 2018;31:263-77. [PMID: 29030886 DOI: 10.1111/tri.13084] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
42 Campagne O, Mager DE, Tornatore KM. Population Pharmacokinetics of Tacrolimus in Transplant Recipients: What Did We Learn About Sources of Interindividual Variabilities? J Clin Pharmacol 2019;59:309-25. [PMID: 30371942 DOI: 10.1002/jcph.1325] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
43 Chen L, Yang Y, Wang X, Wang C, Lin W, Jiao Z, Wang Z. Wuzhi Capsule Dosage Affects Tacrolimus Elimination in Adult Kidney Transplant Recipients, as Determined by a Population Pharmacokinetics Analysis. Pharmgenomics Pers Med 2021;14:1093-106. [PMID: 34511980 DOI: 10.2147/PGPM.S321997] [Reference Citation Analysis]
44 Zhu J, Patel T, Miller JA, Torrice CD, Aggarwal M, Sketch MR, Alexander MD, Armistead PM, Coghill JM, Grgic T, Jamieson KJ, Ptachcinski JR, Riches ML, Serody JS, Schmitz JL, Shaw JR, Shea TC, Suzuki O, Vincent BG, Wood WA, Rao KV, Wiltshire T, Weimer ET, Crona DJ. Influence of Germline Genetics on Tacrolimus Pharmacokinetics and Pharmacodynamics in Allogeneic Hematopoietic Stem Cell Transplant Patients. Int J Mol Sci 2020;21:E858. [PMID: 32013193 DOI: 10.3390/ijms21030858] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
45 Andrews LM, Li Y, De Winter BCM, Shi YY, Baan CC, Van Gelder T, Hesselink DA. Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients. Expert Opin Drug Metab Toxicol 2017;13:1225-36. [PMID: 29084469 DOI: 10.1080/17425255.2017.1395413] [Cited by in Crossref: 59] [Cited by in F6Publishing: 45] [Article Influence: 11.8] [Reference Citation Analysis]
46 Genvigir FD, Salgado PC, Felipe CR, Luo EY, Alves C, Cerda A, Tedesco-Silva H, Medina-Pestana JO, Oliveira N, Rodrigues AC. Influence of the CYP3A4/5 genetic score and ABCB1 polymorphisms on tacrolimus exposure and renal function in Brazilian kidney transplant patients. Pharmacogenet Genomics. 2016;26:462-472. [PMID: 27434656 DOI: 10.1097/fpc.0000000000000237] [Cited by in Crossref: 26] [Cited by in F6Publishing: 10] [Article Influence: 5.2] [Reference Citation Analysis]
47 Freitas RCC, Bortolin RH, Genvigir FDV, Bonezi V, Hirata TDC, Felipe CR, Tedesco-Silva H Jr, Medina-Pestana JO, Cerda A, Doi SQ, Hirata MH, Hirata RDC. Differentially expressed urinary exo-miRs and clinical outcomes in kidney recipients on short-term tacrolimus therapy: a pilot study. Epigenomics 2020;12:2019-34. [PMID: 33275448 DOI: 10.2217/epi-2020-0160] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Wang DD, Chen X, Fu M, Zheng QS, Xu H, Li ZP. Model extrapolation to a real-world dataset: evaluation of tacrolimus population pharmacokinetics and drug interaction in pediatric liver transplantation patients. Xenobiotica 2020;50:371-9. [PMID: 31192749 DOI: 10.1080/00498254.2019.1631505] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
49 Sohn M, Kim MG, Han N, Kim IW, Gim J, Min SI, Song EY, Kim YS, Jung HS, Shin YK, Ha J, Oh JM. Whole exome sequencing for the identification of CYP3A7 variants associated with tacrolimus concentrations in kidney transplant patients. Sci Rep 2018;8:18064. [PMID: 30584253 DOI: 10.1038/s41598-018-36085-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
50 Everton JBF, Patrício FJB, Faria MS, Ferreira TCA, Romao EA, Silva GEB, Magalhães M. CYP3A5 and PPARA genetic variants are associated with low trough concentration to dose ratio of tacrolimus in kidney transplant recipients. Eur J Clin Pharmacol 2021;77:879-86. [PMID: 33398393 DOI: 10.1007/s00228-020-03076-8] [Reference Citation Analysis]
51 Oberbauer R, Bestard O, Furian L, Maggiore U, Pascual J, Rostaing L, Budde K. Optimization of tacrolimus in kidney transplantation: New pharmacokinetic perspectives. Transplant Rev (Orlando) 2020;34:100531. [PMID: 31955920 DOI: 10.1016/j.trre.2020.100531] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
52 Asempa TE, Rebellato LM, Hudson S, Briley K, Maldonado AQ. Impact of CYP3A5 genomic variances on clinical outcomes among African American kidney transplant recipients. Clin Transplant 2018;32. [PMID: 29161757 DOI: 10.1111/ctr.13162] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
53 Chen X, Wang D, Xu H, Li Z. Initial dosage optimization of tacrolimus in Chinese pediatric patients undergoing kidney transplantation based on population pharmacokinetics and pharmacogenetics. Expert Review of Clinical Pharmacology 2020;13:553-61. [DOI: 10.1080/17512433.2020.1767592] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Gervasini G, García-pino G, Vergara E, Mota-zamorano S, García-cerrada M, Luna E. CYP3A genotypes of donors but not those of the patients increase the risk of acute rejection in renal transplant recipients on calcineurin inhibitors: a pilot study. Eur J Clin Pharmacol 2018;74:53-60. [DOI: 10.1007/s00228-017-2353-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
55 Stefanović NZ, Veličković-Radovanović RM, Danković KS, Mitić BP, Paunović GJ, Cvetković MB, Cvetković TP. Combined Effect of Inter- and Intrapatient Variability in Tacrolimus Exposure on Graft Impairment Within a 3-Year Period Following Kidney Transplantation: A Single-Center Experience. Eur J Drug Metab Pharmacokinet 2020;45:749-60. [PMID: 32886348 DOI: 10.1007/s13318-020-00644-2] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
56 Sikma MA, Hunault CC, Van Maarseveen EM, Huitema ADR, Van de Graaf EA, Kirkels JH, Verhaar MC, Grutters JC, Kesecioglu J, De Lange DW. High Variability of Whole-Blood Tacrolimus Pharmacokinetics Early After Thoracic Organ Transplantation. Eur J Drug Metab Pharmacokinet 2020;45:123-34. [PMID: 31745812 DOI: 10.1007/s13318-019-00591-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
57 Lehner LJ, Kleinsteuber A, Halleck F, Khadzhynov D, Schrezenmeier E, Duerr M, Eckardt KU, Budde K, Staeck O. Assessment of the Kidney Donor Profile Index in a European cohort. Nephrol Dial Transplant. 2018;33:1465-1472. [PMID: 29617898 DOI: 10.1093/ndt/gfy030] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
58 Andrews LM, De Winter BC, Van Gelder T, Hesselink DA. Consideration of the ethnic prevalence of genotypes in the clinical use of tacrolimus. Pharmacogenomics 2016;17:1737-40. [PMID: 27790923 DOI: 10.2217/pgs-2016-0136] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
59 Gluba-Brzózka A, Franczyk B, Olszewski R, Banach M, Rysz J. Personalized Medicine: New Perspectives for the Diagnosis and the Treatment of Renal Diseases. Int J Mol Sci 2017;18:E1248. [PMID: 28604601 DOI: 10.3390/ijms18061248] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
60 Kandikattu HK, Venkateshaiah SU, Verma AK, Mishra A. Tacrolimus (FK506) treatment protects allergen-, IL-5- and IL-13-induced mucosal eosinophilia. Immunology 2021;163:220-35. [PMID: 33512727 DOI: 10.1111/imm.13314] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
61 Cheng F, Li Q, Wang J, Zeng F, Zhang Y. Effects and safety evaluation of Wuzhi Capsules combined with tacrolimus for the treatment of kidney transplantation recipients. J Clin Pharm Ther 2021. [PMID: 34342024 DOI: 10.1111/jcpt.13493] [Reference Citation Analysis]
62 Degraeve AL, Moudio S, Haufroid V, Chaib Eddour D, Mourad M, Bindels LB, Elens L. Predictors of tacrolimus pharmacokinetic variability: current evidences and future perspectives. Expert Opin Drug Metab Toxicol 2020;16:769-82. [PMID: 32721175 DOI: 10.1080/17425255.2020.1803277] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
63 Zhang X, Lin G, Tan L, Li J. Current progress of tacrolimus dosing in solid organ transplant recipients: Pharmacogenetic considerations. Biomedicine & Pharmacotherapy 2018;102:107-14. [DOI: 10.1016/j.biopha.2018.03.054] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
64 Wang D, Chen X, Li Z. Wuzhi capsule and haemoglobin influence tacrolimus elimination in paediatric kidney transplantation patients in a population pharmacokinetics analysis: A retrospective study. J Clin Pharm Ther 2019;44:611-7. [DOI: 10.1111/jcpt.12828] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
65 Oetting WS, Wu B, Schladt DP, Guan W, Remmel RP, Dorr C, Mannon RB, Matas AJ, Israni AK, Jacobson PA. Attempted validation of 44 reported SNPs associated with tacrolimus troughs in a cohort of kidney allograft recipients. Pharmacogenomics 2018;19:175-84. [PMID: 29318894 DOI: 10.2217/pgs-2017-0187] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
66 Zhang X, Men T, Liu H, Li X, Wang J, Lv J. Genetic risk factors for post-transplantation diabetes mellitus in Chinese Han renal allograft recipients treated with tacrolimus. Transpl Immunol 2018;49:39-42. [PMID: 29665413 DOI: 10.1016/j.trim.2018.04.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
67 Campagne O, Mager DE, Brazeau D, Venuto RC, Tornatore KM. The impact of tacrolimus exposure on extrarenal adverse effects in adult renal transplant recipients. Br J Clin Pharmacol 2019;85:516-29. [PMID: 30414331 DOI: 10.1111/bcp.13811] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
68 Pihlstrøm HK, Mjøen G, Mucha S, Franke A, Jardine A, Fellström B, Dahle DO, Holdaas H, Melum E. Genetic markers associated with long-term cardiovascular outcome in kidney transplant recipients. Am J Transplant 2019;19:1444-51. [PMID: 30457209 DOI: 10.1111/ajt.15191] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
69 Si S, Wang Z, Yang H, Han Z, Tao J, Chen H, Wang K, Guo M, Tan R, Wei JF, Gu M. Impact of single nucleotide polymorphisms on P450 oxidoreductase and peroxisome proliferator-activated receptor alpha on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenomics J 2019;19:42-52. [PMID: 30323313 DOI: 10.1038/s41397-018-0061-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
70 Brazeau DA, Attwood K, Meaney CJ, Wilding GE, Consiglio JD, Chang SS, Gundroo A, Venuto RC, Cooper L, Tornatore KM. Beyond Single Nucleotide Polymorphisms: CYP3A5367 Composite and ABCB1 Haplotype Associations to Tacrolimus Pharmacokinetics in Black and White Renal Transplant Recipients. Front Genet 2020;11:889. [PMID: 32849848 DOI: 10.3389/fgene.2020.00889] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 van Willigenburg H, de Keizer PLJ, de Bruin RWF. Cellular senescence as a therapeutic target to improve renal transplantation outcome. Pharmacol Res 2018;130:322-30. [PMID: 29471104 DOI: 10.1016/j.phrs.2018.02.015] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
72 Almeida-paulo GN, Dapía García I, Lubomirov R, Borobia AM, Alonso-sánchez NL, Espinosa L, Carcas-sansuán AJ. Weight of ABCB1 and POR genes on oral tacrolimus exposure in CYP3A5 nonexpressor pediatric patients with stable kidney transplant. Pharmacogenomics J 2018;18:180-6. [DOI: 10.1038/tpj.2016.93] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]